EligibleTrials

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

Recruiting · NCT07619131 · Interventional (participants receive a specific treatment)

View the official record on ClinicalTrials.gov →
High cholesterol

Interventions studied

LaroprovstatLaroprovstat/Rosuvastatin 1Laroprovstat/Rosuvastatin 2Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1Placebo to match Laroprovstat/Rosuvastatin 2Placebo to match rosuvastatinRosuvastatin 1Rosuvastatin 2

What this trial is about

This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.

Who can take part

Age range
18 Years to 130 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed across 29 US states.

Showing 60 of 152 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.